• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Gastroenterology

Similar outcomes between laparoscopic and open surgery for rectal cancer [COLOR II trial]

byTomi JunandMatthew Growdon
April 2, 2015
in Gastroenterology, Surgery
Reading Time: 2 mins read
Laparoscopic colon cancer management may be beneficial in elderly
Share on FacebookShare on TwitterShare on LinkedIn

1. There were no statistically significant differences in locoregional recurrence, disease-free survival or overall survival after 3 years between laparoscopic and open surgery for rectal cancer.

2. Disease-free survival was significantly higher among patients with stage III rectal cancer who had undergone laparoscopic surgery compared to those who had undergone open surgery.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Randomized trials have shown that laparoscopic surgery can achieve similar rates of long-term survival as open surgery for colon cancer, as well as favorable short-term outcomes including less pain, reduced blood loss, and improved recovery time. A growing body of evidence suggests that the same is true for rectal cancer, though this has not been definitively established.

The Colorectal Cancer Laparoscopic or Open Resection (COLOR) II study compared laparoscopic surgery against open surgery for rectal cancer. At 3 years after surgery, the locoregional recurrence was the same in both groups (5%), and there was no difference in disease-free or overall survival between the two groups.

This study is larger than two prior trials (CLASICC and COREAN) to look at this issue; the concordance of findings from these studies further lends credence to the conclusion that laparoscopic surgery is as safe and effective as open surgery in the treatment of rectal cancer.

RELATED REPORTS

2 Minute Medicine Rewind April 27, 2026

Atezolizumab may improve disease-free survival in mismatch repair deficiency locally advanced colon cancer

Click to read the study, published today in NEJM

Relevant Reading: Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial; Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial

In-Depth [randomized controlled trial]: COLOR II enrolled 1103 patients with rectal cancer between 2004 and 2010. Candidates for the trial had to have solitary rectal tumors within 15cm of the anal verge and be candidates for elective surgery. Patients with tumors extending through the wall of the rectum or involving adjacent tissues (T3 or T4 on imaging) were excluded. Participants were randomized in a 2:1 ratio to laparoscopic or open surgery.

The primary outcome was locoregional recurrence after 3 years. This was the same (5%) between both groups. Non-inferiority of laparoscopic surgery was established since the upper limit of the one-sided 95% confidence interval for the absolute difference was 2.6 percentage points, which did not exceed the pre-specified threshold of 5 percentage points for non-inferiority.

Secondary outcomes were disease-free and overall survival. Disease-free survival was 74.8% vs. 70.8% (95% CI for absolute difference -1.9 to 9.9) for laparoscopic and open surgery respectively. Overall survival was 86.7% vs. 83.6% (95% CI for absolute difference -1.6 to 7.8) for laparoscopic and open surgery respectively. Of note, disease-free survival was significantly higher among patients with stage III disease who had undergone laparoscopic surgery (64.9% vs. 52%, 95% CI for absolute difference 2.2 to 23.6).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: colon cancer
Previous Post

Elective egg freezing a cost-effective strategy to delay child bearing

Next Post

Corticosteroid injections ineffective for exercise pain in knee osteoarthritis

RelatedReports

Development of a risk index for colorectal cancer screening
Weekly Rewinds

2 Minute Medicine Rewind April 27, 2026

April 27, 2026
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Oncology

Atezolizumab may improve disease-free survival in mismatch repair deficiency locally advanced colon cancer

April 8, 2026
Development of a risk index for colorectal cancer screening
Chronic Disease

Neoadjuvant chemotherapy does not improve disease-free survival in patients with locally advanced colon cancer

March 25, 2026
#VisualAbstract: 3-Year Structured Exercise after Adjuvant Chemotherapy Improved Survival for Colon Cancer
StudyGraphics

#VisualAbstract: 3-Year Structured Exercise after Adjuvant Chemotherapy Improved Survival for Colon Cancer

August 7, 2025
Next Post
Intra-articular injection therapies most effective at controlling knee osteoarthritis pain

Corticosteroid injections ineffective for exercise pain in knee osteoarthritis

Shortened tuberculosis treatment regimen inferior to standard

Xpert MTB/RIF assay more sensitive than smear microscopy for diagnosing tuberculosis

Classics Series, Landmark Trials in Medicine

The ACURASYS trial: Neuromuscular blockade in early ARDS [Classics Series]

✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Optogenetic therapy may partially restore vision in retinitis pigmentosa
  • An artificial intelligence system for human papillomavirus-positive dual stain cervical cancer screening reads p16-Ki67 slides
  • Elevated low-density lipoprotein cholesterol is a risk factor for atherosclerotic disease irrespective of familial hypercholesterolemia status
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.